Pharmaceuticals, Biotechnology and Life Sciences
LONDON–(BUSINESS WIRE)–#Biotechnology–Technavio has been monitoring the peptide therapeutics market and it is poised to grow by USD 16 billion during…
CAMBRIDGE, Mass. & SALISBURY, England–(BUSINESS WIRE)–$KALV–KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development,…
Primary and secondary endpoints met in both TRuE-AD1 and TRuE-AD2 WILMINGTON, Del.–(BUSINESS WIRE)–$INCY–Incyte (Nasdaq:INCY) today announced that the second randomized,…
-Phase 1 study demonstrated TERN-101 is safe and exhibits potent target engagement at all dose levels studied- -Phase 2 studies…
Mereo BioPharma has entered into a Securities Purchase Agreement with a new U.S.-based institutional healthcare investor. Under the terms of the Agreement, the institutional investor has agreed to make an investment of $3 million to purchase 12,252,715 of the Company’s ordinary shares (equivalent to 2,450,543 American Depository shares (ADSs)) at a price equivalent to 18.8 pence per share, which represents a 20% discount over Mereo’s closing share price of 23.5 pence on AIM on February 18, 2020.
SOMERSET, N.J.–(BUSINESS WIRE)–Catalent, Inc. (“Catalent”) (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for…
Unparalleled HealthTech forum helps drive and foster collaborations within the European healthcare and life sciences ecosystems to advance and accelerate…
New Chief Medical Officer has a deep expertise in gene therapy and small molecule clinical development across disease areas Appointment…
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that…
Combining Leading Genetics Library With Proprietary, Commercial Scale Propagation Technology Sets Stage for Fundamental Changes in Hemp and Cannabis Markets…